{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T13:40:22Z","timestamp":1759066822452,"version":"3.44.0"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Behavioural Brain Research"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.bbr.2019.112315","type":"journal-article","created":{"date-parts":[[2019,10,22]],"date-time":"2019-10-22T20:38:19Z","timestamp":1571776699000},"page":"112315","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["ASP2905, a specific inhibitor of the potassium channel Kv12.2 encoded by the Kcnh3 gene, is psychoactive in mice"],"prefix":"10.1016","volume":"378","author":[{"given":"Shinji","family":"Takahashi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ai","family":"Okamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayako","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keni","family":"Ni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbr.2019.112315_bib0005","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/epirev\/mxn001","article-title":"Schizophrenia: a concise overview of incidence, prevalence, and mortality","volume":"30","author":"McGrath","year":"2008","journal-title":"Epidemiol. Rev."},{"issue":"9162","key":"10.1016\/j.bbr.2019.112315_bib0010","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/S0140-6736(98)07549-7","article-title":"Schizophrenia","volume":"353","author":"Schultz","year":"1999","journal-title":"Lancet (London, England)"},{"issue":"1","key":"10.1016\/j.bbr.2019.112315_bib0015","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/sj.mp.4001556","article-title":"Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs","volume":"10","author":"Miyamoto","year":"2005","journal-title":"Mol. Psychiatry"},{"issue":"4238","key":"10.1016\/j.bbr.2019.112315_bib0020","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1126\/science.3854","article-title":"Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs","volume":"192","author":"Creese","year":"1976","journal-title":"Science (New York, N.Y.)"},{"issue":"5562","key":"10.1016\/j.bbr.2019.112315_bib0025","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/261717a0","article-title":"Antipsychotic drug doses and neuroleptic\/dopamine receptors","volume":"261","author":"Seeman","year":"1976","journal-title":"Nature"},{"issue":"Suppl. 8","key":"10.1016\/j.bbr.2019.112315_bib0030","first-page":"5","article-title":"An overview of side effects caused by typical antipsychotics","volume":"61","author":"Arana","year":"2000","journal-title":"J. Clin. Psychiatry"},{"issue":"9657","key":"10.1016\/j.bbr.2019.112315_bib0035","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","article-title":"Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis","volume":"373","author":"Leucht","year":"2009","journal-title":"Lancet (London, England)"},{"issue":"2","key":"10.1016\/j.bbr.2019.112315_bib0040","first-page":"44","article-title":"Clinical efficacy of clozapine in the treatment of schizophrenia","volume":"24","author":"Meltzer","year":"1991","journal-title":"Pharmacopsychiatry"},{"issue":"9","key":"10.1016\/j.bbr.2019.112315_bib0045","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","article-title":"Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine","volume":"45","author":"Kane","year":"1988","journal-title":"Arch. Gen. Psychiatry"},{"issue":"12","key":"10.1016\/j.bbr.2019.112315_bib0050","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1038\/mp.2012.47","article-title":"Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents","volume":"17","author":"Miyamoto","year":"2012","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.bbr.2019.112315_bib0055","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s40501-016-0075-8","article-title":"Treating negative symptoms in schizophrenia: an update","volume":"3","author":"Remington","year":"2016","journal-title":"Curr. Treat. Options Psychiatry"},{"issue":"7","key":"10.1016\/j.bbr.2019.112315_bib0060","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1176\/ajp.2007.164.7.1061","article-title":"Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison","volume":"164","author":"Keefe","year":"2007","journal-title":"Am. J. Psychiatry"},{"issue":"2\u20133","key":"10.1016\/j.bbr.2019.112315_bib0065","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.schres.2013.07.026","article-title":"Pharmacological approaches to treating negative symptoms: a review of clinical trials","volume":"150","author":"Arango","year":"2013","journal-title":"Schizophr. Res."},{"issue":"4","key":"10.1016\/j.bbr.2019.112315_bib0070","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1093\/schbul\/sbu170","article-title":"Treatments of negative symptoms in schizophrenia: meta-analysis of 168 randomized placebo-controlled trials","volume":"41","author":"Fusar-Poli","year":"2015","journal-title":"Schizophr. Bull."},{"issue":"10","key":"10.1016\/j.bbr.2019.112315_bib0075","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1001\/jamapsychiatry.2013.155","article-title":"Schizophrenia is a cognitive illness: time for a change in focus","volume":"70","author":"Kahn","year":"2013","journal-title":"JAMA Psychiatry"},{"issue":"6","key":"10.1016\/j.bbr.2019.112315_bib0080","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1176\/appi.ajp.2008.08060806","article-title":"Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST)","volume":"166","author":"Davidson","year":"2009","journal-title":"Am. J. Psychiatry"},{"issue":"1\u20133","key":"10.1016\/j.bbr.2019.112315_bib0085","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.schres.2007.11.014","article-title":"A randomized double-blind comparison of ziprasidone vs. Clozapine for cognition in patients with schizophrenia selected for resistance or intolerance to previous treatment","volume":"105","author":"Harvey","year":"2008","journal-title":"Schizophr. Res."},{"issue":"9896","key":"10.1016\/j.bbr.2019.112315_bib0090","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet (London, England)"},{"issue":"3","key":"10.1016\/j.bbr.2019.112315_bib0095","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/acps.12374","article-title":"Second-generation antipsychotic effect on cognition in patients with schizophrenia--a meta-analysis of randomized clinical trials","volume":"131","author":"Nielsen","year":"2015","journal-title":"Acta Psychiatr. Scand."},{"issue":"1","key":"10.1016\/j.bbr.2019.112315_bib0100","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.pnpbp.2010.08.018","article-title":"Quality of life and cognitive dysfunction in people with schizophrenia","volume":"35","author":"Ueoka","year":"2011","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.bbr.2019.112315_bib0105","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1177\/0020764011423465","article-title":"Typology of schizophrenic symptoms and quality of life in patients and their main caregivers in northern Chile","volume":"59","author":"Caqueo-Urizar","year":"2013","journal-title":"Int. J. Soc. Psychiatry"},{"key":"10.1016\/j.bbr.2019.112315_bib0110","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ejphar.2017.05.045","article-title":"Neurochemical and neuropharmacological characterization of ASP2905, a novel potent selective inhibitor of the potassium channel KCNH3","volume":"810","author":"Takahashi","year":"2017","journal-title":"Eur. J. Pharmacol."},{"issue":"35","key":"10.1016\/j.bbr.2019.112315_bib0115","doi-asserted-by":"crossref","first-page":"25018","DOI":"10.1074\/jbc.274.35.25018","article-title":"New ether-a-go-go K(+) channel family members localized in human telencephalon","volume":"274","author":"Miyake","year":"1999","journal-title":"J. Biol. Chem."},{"year":"1991","series-title":"The Neuron: Cell and Molecular Biology","author":"Levitan","key":"10.1016\/j.bbr.2019.112315_bib0120"},{"issue":"13","key":"10.1016\/j.bbr.2019.112315_bib0125","doi-asserted-by":"crossref","first-page":"4609","DOI":"10.1523\/JNEUROSCI.21-13-04609.2001","article-title":"Differential expression of genes encoding subthreshold-operating voltage-gated K+ channels in brain","volume":"21","author":"Saganich","year":"2001","journal-title":"J. Neurosci."},{"issue":"46","key":"10.1016\/j.bbr.2019.112315_bib0130","doi-asserted-by":"crossref","first-page":"14637","DOI":"10.1523\/JNEUROSCI.0901-09.2009","article-title":"Disruption of the ether-a-go-go K+ channel gene BEC1\/KCNH3 enhances cognitive function","volume":"29","author":"Miyake","year":"2009","journal-title":"J. Neurosci."},{"issue":"4","key":"10.1016\/j.bbr.2019.112315_bib0135","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0893-133X(00)00138-X","article-title":"Repeated phencyclidine treatment induces negative symptom-like behavior in forced swimming test in mice: imbalance of prefrontal serotonergic and dopaminergic functions","volume":"23","author":"Noda","year":"2000","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"10.1016\/j.bbr.2019.112315_bib0140","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0893-133X(00)00192-5","article-title":"Phencyclidine impairs latent learning in mice: interaction between glutamatergic systems and sigma(1) receptors","volume":"24","author":"Noda","year":"2001","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bbr.2019.112315_bib0145","article-title":"Evaluation of drugs for cognitive disorders using a one-trial water-finding task in mice","author":"Takahashi","year":"2004","journal-title":"34th Soc Neurosci Abstr Program No. 898.2"},{"issue":"5","key":"10.1016\/j.bbr.2019.112315_bib0150","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1111\/j.1476-5381.1995.tb15106.x","article-title":"Enhancement of immobility in a forced swimming test by subacute or repeated treatment with phencyclidine: a new model of schizophrenia","volume":"116","author":"Noda","year":"1995","journal-title":"Br. J. Pharmacol."},{"issue":"7","key":"10.1016\/j.bbr.2019.112315_bib0155","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/S0028-3908(99)00214-2","article-title":"PD 158771, a potential antipsychotic agent with D2\/D3 partial agonist and 5-HT(1A) agonist actions. II. Preclinical behavioral effects","volume":"39","author":"Corbin","year":"2000","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.bbr.2019.112315_bib0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00213-006-0577-y","article-title":"The drug-induced helplessness test: an animal assay for assessing behavioral despair in response to neuroleptic treatment","volume":"190","author":"Ballard","year":"2007","journal-title":"Psychopharmacology"},{"issue":"2-3","key":"10.1016\/j.bbr.2019.112315_bib0165","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0014-2999(97)00067-8","article-title":"Effects of antidepressants on phencyclidine-induced enhancement of immobility in a forced swimming test in mice","volume":"324","author":"Noda","year":"1997","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bbr.2019.112315_bib0170","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1196\/annals.1377.003","article-title":"Animal model of schizophrenia: dysfunction of NMDA receptor-signaling in mice following withdrawal from repeated administration of phencyclidine","volume":"1086","author":"Nabeshima","year":"2006","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"3","key":"10.1016\/j.bbr.2019.112315_bib0175","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.neuropharm.2007.05.026","article-title":"Synergistic effect of combined treatment with risperidone and galantamine on phencyclidine-induced impairment of latent visuospatial learning and memory: role of nAChR activation-dependent increase of dopamine D1 receptor-mediated neurotransmission","volume":"53","author":"Wang","year":"2007","journal-title":"Neuropharmacology"},{"issue":"6","key":"10.1016\/j.bbr.2019.112315_bib0180","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1124\/mol.106.032961","article-title":"Involvement of a dysfunctional dopamine-D1\/N-methyl-d-aspartate-NR1 and Ca2+\/calmodulin-dependent protein kinase II pathway in the impairment of latent learning in a model of schizophrenia induced by phencyclidine","volume":"71","author":"Mouri","year":"2007","journal-title":"Mol. Pharmacol."},{"issue":"1","key":"10.1016\/j.bbr.2019.112315_bib0185","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/S0022-3565(25)10241-3","article-title":"Dopaminergic agonists impair latent learning in mice: possible modulation by noradrenergic function","volume":"264","author":"Ichihara","year":"1993","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"11","key":"10.1016\/j.bbr.2019.112315_bib0190","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1038\/sj.npp.1300772","article-title":"Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic","volume":"30","author":"Depoortere","year":"2005","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"10.1016\/j.bbr.2019.112315_bib0195","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s00213-007-0742-y","article-title":"Stimulation of the metabotropic glutamate 2\/3 receptor attenuates social novelty discrimination deficits induced by neonatal phencyclidine treatment","volume":"192","author":"Harich","year":"2007","journal-title":"Psychopharmacology"},{"issue":"3","key":"10.1016\/j.bbr.2019.112315_bib0200","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0893-133X(00)00137-8","article-title":"To model a psychiatric disorder in animals: schizophrenia as a reality test","volume":"23","author":"Lipska","year":"2000","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.bbr.2019.112315_bib0205","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0306-4522(01)00171-3","article-title":"Translating developmental time across mammalian species","volume":"105","author":"Clancy","year":"2001","journal-title":"Neuroscience"},{"issue":"2","key":"10.1016\/j.bbr.2019.112315_bib0210","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1002\/(SICI)1098-2396(199706)26:2<104::AID-SYN2>3.0.CO;2-C","article-title":"Effect of chronic administration of NMDA antagonists on synaptic development","volume":"26","author":"Brooks","year":"1997","journal-title":"Synapse (New York, N.Y.)"},{"issue":"6","key":"10.1016\/j.bbr.2019.112315_bib0215","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1038\/sj.npp.1300394","article-title":"Spatial memory deficits induced by perinatal treatment of rats with PCP and reversal effect of D-serine","volume":"29","author":"Andersen","year":"2004","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"10.1016\/j.bbr.2019.112315_bib0220","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0031-9384(97)00169-8","article-title":"Altered NMDA sensitivity and learning following chronic developmental NMDA antagonism","volume":"62","author":"Brooks","year":"1997","journal-title":"Physiol. Behav."},{"issue":"4","key":"10.1016\/j.bbr.2019.112315_bib0225","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0306-4522(01)00384-0","article-title":"Long-term behavioral and neurodegenerative effects of perinatal phencyclidine administration: implications for schizophrenia","volume":"107","author":"Wang","year":"2001","journal-title":"Neuroscience"},{"issue":"11","key":"10.1016\/j.bbr.2019.112315_bib0230","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0207750","article-title":"The KCNH3 inhibitor ASP2905 shows potential in the treatment of attention deficit\/hyperactivity disorder","volume":"13","author":"Takahashi","year":"2018","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.bbr.2019.112315_bib0235","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.neubiorev.2008.03.003","article-title":"Behavioural and neurochemical effects of post-weaning social isolation in rodents-relevance to developmental neuropsychiatric disorders","volume":"32","author":"Fone","year":"2008","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"1","key":"10.1016\/j.bbr.2019.112315_bib0240","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/schbul\/sbr133","article-title":"Is the acute NMDA receptor hypofunction a valid model of schizophrenia?","volume":"38","author":"Adell","year":"2012","journal-title":"Schizophr. Bull."},{"issue":"3","key":"10.1016\/j.bbr.2019.112315_bib0245","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/aps.2015.105","article-title":"Y-QA31, a novel dopamine D3 receptor antagonist, exhibits antipsychotic-like properties in preclinical animal models of schizophrenia","volume":"37","author":"Sun","year":"2016","journal-title":"Acta Pharmacol. Sin."},{"issue":"10","key":"10.1016\/j.bbr.2019.112315_bib0250","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1176\/ajp.148.10.1301","article-title":"Recent advances in the phencyclidine model of schizophrenia","volume":"148","author":"Javitt","year":"1991","journal-title":"Am. J. Psychiatry"},{"issue":"18","key":"10.1016\/j.bbr.2019.112315_bib0255","doi-asserted-by":"crossref","first-page":"l285","DOI":"10.1016\/0024-3205(93)90588-T","article-title":"NE-100, a novel sigma receptor ligand: in vivo tests","volume":"53","author":"Okuyama","year":"1993","journal-title":"Life Sci."},{"issue":"1","key":"10.1016\/j.bbr.2019.112315_bib0260","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s002130050165","article-title":"Blockade of phencyclidine-induced hyperlocomotion by olanzapine, clozapine and serotonin receptor subtype selective antagonists in mice","volume":"129","author":"Gleason","year":"1997","journal-title":"Psychopharmacology"},{"issue":"6","key":"10.1016\/j.bbr.2019.112315_bib0265","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/S0006-3223(98)00356-4","article-title":"Involvement of serotonin 2A receptors in phencyclidine-induced disruption of prepulse inhibition of the acoustic startle in rats","volume":"46","author":"Yamada","year":"1999","journal-title":"Biol. Psychiatry"},{"issue":"3","key":"10.1016\/j.bbr.2019.112315_bib0270","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s00213-012-2838-2","article-title":"Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study","volume":"225","author":"Ogasa","year":"2013","journal-title":"Psychopharmacology"},{"issue":"Suppl. 2","key":"10.1016\/j.bbr.2019.112315_bib0275","doi-asserted-by":"crossref","first-page":"S108","DOI":"10.1016\/j.euroneuro.2007.02.004","article-title":"Management of agitation in the acute psychotic patient--efficacy without excessive sedation","volume":"17","author":"Canas","year":"2007","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"5","key":"10.1016\/j.bbr.2019.112315_bib0280","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1177\/2042098618756261","article-title":"Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine","volume":"9","author":"De Berardis","year":"2018","journal-title":"Ther. Adv. Drug Saf."},{"issue":"11","key":"10.1016\/j.bbr.2019.112315_bib0285","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1176\/ajp.148.11.1474","article-title":"Dopamine in schizophrenia: a review and reconceptualization","volume":"148","author":"Davis","year":"1991","journal-title":"Am. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.bbr.2019.112315_bib0290","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.pnpbp.2006.11.013","article-title":"The n-3 polyunsaturated fatty acid\/dopamine hypothesis of schizophrenia","volume":"31","author":"Ohara","year":"2007","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.bbr.2019.112315_bib0295","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0304-3940(98)00841-6","article-title":"Dopamine and acetylcholine elevation on lever-press acquisition in rat prefrontal cortex","volume":"258","author":"Izaki","year":"1998","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.bbr.2019.112315_bib0300","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3389\/fncir.2014.00017","article-title":"Cholinergic modulation of the medial prefrontal cortex: the role of nicotinic receptors in attention and regulation of neuronal activity","volume":"8","author":"Bloem","year":"2014","journal-title":"Front. Neural Circuits"},{"issue":"3","key":"10.1016\/j.bbr.2019.112315_bib0305","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1523\/JNEUROSCI.20-03-01208.2000","article-title":"Enhanced and impaired attentional performance after infusion of D1 dopaminergic receptor agents into rat prefrontal cortex","volume":"20","author":"Granon","year":"2000","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bbr.2019.112315_bib0310","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3389\/fncir.2018.00031","article-title":"Relationship between neuromodulation and working memory in the prefrontal cortex: it\u2019s complicated","volume":"12","author":"Motley","year":"2018","journal-title":"Front. Neural Circuits"},{"issue":"4","key":"10.1016\/j.bbr.2019.112315_bib0315","first-page":"176","article-title":"The pharmacodynamic properties of lorazepam and methylphenidate drugs on event-related potentials and power spectral analysis in normal subjects","volume":"17","author":"Berchou","year":"1986","journal-title":"Clin. Electroencephalogr."},{"issue":"2","key":"10.1016\/j.bbr.2019.112315_bib0320","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s00213-002-1315-8","article-title":"Distinctive effects of modafinil and d-amphetamine on the homeostatic and circadian modulation of the human waking EEG","volume":"166","author":"Chapotot","year":"2003","journal-title":"Psychopharmacology"}],"container-title":["Behavioural Brain Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166432819306254?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166432819306254?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T13:16:51Z","timestamp":1759065411000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166432819306254"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":64,"alternative-id":["S0166432819306254"],"URL":"https:\/\/doi.org\/10.1016\/j.bbr.2019.112315","relation":{},"ISSN":["0166-4328"],"issn-type":[{"type":"print","value":"0166-4328"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ASP2905, a specific inhibitor of the potassium channel Kv12.2 encoded by the Kcnh3 gene, is psychoactive in mice","name":"articletitle","label":"Article Title"},{"value":"Behavioural Brain Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbr.2019.112315","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"112315"}}